A detailed history of Royal London Asset Management LTD transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Royal London Asset Management LTD holds 876,982 shares of GILD stock, worth $81.2 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares
876,982
Previous 899,509 2.5%
Holding current value
$81.2 Million
Previous $61.7 Million 19.11%
% of portfolio
0.19%
Previous 0.16%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$66.59 - $83.99 $1.5 Million - $1.89 Million
-22,527 Reduced 2.5%
876,982 $73.5 Million
Q2 2024

Aug 07, 2024

SELL
$63.15 - $72.88 $20.4 Million - $23.5 Million
-322,725 Reduced 26.4%
899,509 $61.7 Million
Q1 2024

May 14, 2024

BUY
$71.58 - $87.29 $12.7 Million - $15.5 Million
177,359 Added 16.97%
1,222,234 $89.5 Million
Q4 2023

Feb 13, 2024

BUY
$73.27 - $83.09 $14.8 Million - $16.7 Million
201,545 Added 23.9%
1,044,875 $84.6 Million
Q3 2023

Nov 14, 2023

BUY
$73.94 - $80.67 $16.5 Million - $18 Million
223,694 Added 36.1%
843,330 $63.2 Million
Q2 2023

Aug 11, 2023

BUY
$76.01 - $86.7 $3.06 Million - $3.49 Million
40,233 Added 6.94%
619,636 $47.8 Million
Q1 2023

May 15, 2023

SELL
$77.31 - $88.08 $3.97 Million - $4.52 Million
-51,328 Reduced 8.14%
579,403 $48.1 Million
Q4 2022

Feb 09, 2023

BUY
$62.32 - $89.47 $563,996 - $809,703
9,050 Added 1.46%
630,731 $54.1 Million
Q3 2022

Nov 14, 2022

SELL
$59.54 - $68.01 $1.92 Million - $2.19 Million
-32,231 Reduced 4.93%
621,681 $38.4 Million
Q2 2022

Aug 12, 2022

SELL
$57.72 - $65.01 $81,096 - $91,339
-1,405 Reduced 0.21%
653,912 $40.4 Million
Q1 2022

May 13, 2022

BUY
$57.92 - $72.58 $1.45 Million - $1.82 Million
25,011 Added 3.97%
655,317 $39 Million
Q4 2021

Oct 18, 2022

SELL
$64.88 - $73.64 $1.75 Million - $1.99 Million
-27,025 Reduced 4.11%
630,306 $45.8 Million
Q4 2021

Jan 18, 2022

SELL
$64.88 - $73.64 $1.75 Million - $1.99 Million
-27,025 Reduced 4.11%
630,306 $45.8 Million
Q3 2021

Oct 18, 2022

SELL
$67.69 - $73.03 $1.17 Million - $1.27 Million
-17,327 Reduced 2.57%
657,331 $45.9 Million
Q3 2021

Nov 02, 2021

SELL
$67.69 - $73.03 $1.17 Million - $1.27 Million
-17,327 Reduced 2.57%
657,331 $45.9 Million
Q2 2021

Oct 18, 2022

BUY
$63.47 - $69.35 $1.32 Million - $1.44 Million
20,746 Added 3.17%
674,658 $46.4 Million
Q2 2021

Jul 14, 2021

SELL
$63.47 - $69.35 $1.11 Million - $1.21 Million
-17,429 Reduced 2.52%
674,658 $46.6 Million
Q1 2021

Oct 17, 2022

BUY
$60.0 - $68.46 $2.29 Million - $2.61 Million
38,175 Added 5.84%
692,087 $44.7 Million
Q1 2021

Apr 13, 2021

BUY
$60.0 - $68.46 $1.29 Million - $1.47 Million
21,515 Added 3.21%
692,087 $44.7 Million
Q4 2020

Jan 29, 2021

BUY
$56.65 - $64.55 $40,844 - $46,540
721 Added 0.11%
670,572 $39.1 Million
Q3 2020

Nov 04, 2020

SELL
$62.1 - $78.08 $112,959 - $142,027
-1,819 Reduced 0.27%
669,851 $41.6 Million
Q2 2020

Jul 31, 2020

SELL
$72.34 - $84.0 $1.33 Million - $1.54 Million
-18,363 Reduced 2.66%
671,670 $50.1 Million
Q1 2020

May 01, 2020

BUY
$62.63 - $80.22 $214,006 - $274,111
3,417 Added 0.5%
690,033 $52.4 Million
Q4 2019

Feb 05, 2020

BUY
$61.62 - $67.78 $1.31 Million - $1.44 Million
21,284 Added 3.2%
686,616 $44.6 Million
Q3 2019

Nov 12, 2019

BUY
$62.51 - $69.0 $138,209 - $152,559
2,211 Added 0.33%
665,332 $42.2 Million
Q2 2019

Jul 31, 2019

SELL
$61.87 - $69.38 $1.29 Million - $1.45 Million
-20,914 Reduced 3.06%
663,121 $44.8 Million
Q1 2019

Apr 30, 2019

BUY
$62.53 - $70.05 $833,212 - $933,416
13,325 Added 1.99%
684,035 $0
Q4 2018

Jan 29, 2019

BUY
$60.54 - $79.0 $7.91 Million - $10.3 Million
130,585 Added 24.18%
670,710 $41.5 Million
Q3 2018

Nov 08, 2018

SELL
$71.28 - $78.92 $878,383 - $972,531
-12,323 Reduced 2.23%
540,125 $0
Q2 2018

Sep 19, 2018

BUY
$64.88 - $75.68 $35.8 Million - $41.8 Million
552,448 New
552,448 $39.1 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $116B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Royal London Asset Management LTD Portfolio

Follow Royal London Asset Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal London Asset Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Royal London Asset Management LTD with notifications on news.